ProKidney (NASDAQ:PROK – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare ProKidney to similar companies based on the strength of its dividends, valuation, earnings, profitability, institutional ownership, analyst recommendations and risk.
Insider and Institutional Ownership
51.6% of ProKidney shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 39.8% of ProKidney shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares ProKidney and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProKidney | -13,326.71% | N/A | -35.31% |
| ProKidney Competitors | -12,319.70% | -407.93% | -30.95% |
Analyst Recommendations
This is a summary of recent recommendations for ProKidney and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProKidney | 1 | 0 | 2 | 1 | 2.75 |
| ProKidney Competitors | 9931 | 15324 | 45730 | 1605 | 2.54 |
ProKidney currently has a consensus price target of $10.00, indicating a potential upside of 830.23%. As a group, “Biotechnology” companies have a potential upside of 134.12%. Given ProKidney’s stronger consensus rating and higher possible upside, equities research analysts plainly believe ProKidney is more favorable than its rivals.
Volatility and Risk
ProKidney has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, ProKidney’s rivals have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.
Earnings & Valuation
This table compares ProKidney and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| ProKidney | $890,000.00 | -$68.99 million | -1.79 |
| ProKidney Competitors | $715.39 million | $10.31 million | -18.32 |
ProKidney’s rivals have higher revenue and earnings than ProKidney. ProKidney is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
ProKidney beats its rivals on 8 of the 13 factors compared.
About ProKidney
ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment.
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
